We no longer support this browser. Using a supported browser will provide a better experience.

Please update your browser.

Close browser message

Coronavirus research

This compilation includes all of our research to-date on the coronavirus. High frequency charts on infection, mortality, economic and market data are updated as data becomes available, usually on a daily basis.

What’s new: Tracking infections vs mortality in the US and across the globe (Section 2); Positive clinical evidence for anticoagulants, ACE inhibitors, convalescent plasma and monoclonal antibodies (Section 4); Detailed reports by state: infections, hospitalization, mortality, hospital utilization and testing (Section 6).

Our research to-date on the coronavirus

  1. The US reopens: tracking US citizens and consumers >
  2. COVID-19 infection tracker and mortality tracker >
  3. COVID impact on markets: stimulus and valuations >
  4. COVID Drug Development >
  5. COVID: testing for the virus and for antibodies, T-cell immune memory and survivor impacts >
  6. Detailed virus reports by state >

 

 

1. The US reopens: tracking US citizens and consumers

  • High frequency recovery tracking (mobility, manufacturing, retail, air travel, geolocation, oil, hotels, housing, etc.)
  • Real time credit and debit spending data

Get the PDF

 

 

2. COVID-19 infection tracker and mortality tracker

  • Global COVID infection snapshot (trends, declines from peak levels, threshold levels)
  • US hotspot tracking: infections, hospitalizations, mortality, testing and doctor visits
  • Infection and mortality time series by country

Get the PDF

 

 

3. COVID impact on markets: stimulus and valuations

  • Stimulus impact on credit and equity valuations
  • Special focus: COVID and the unfunded obligations of US states
  • Special focus: what are the ECB and European Governments doing?
  • Special focus: A long history of market bottoms

Get the PDF

 

 

4. COVID drug development

  • The latest news on anti-virals, vaccines, monoclonal antibodies, convalescent plasma and corticosteroids
  • Potential benefits of anticoagulants, statins and ACE inhibitors for infected patients

Get the PDF

 

 

5. COVID: testing for the virus and for antibodies, T-cell immune memory and survivor impacts

  • How virus testing and antibody testing work
  • Latest regional serology results and implications for higher levels of immunity
  • Pre-existing T-cell immune memory and COVID
  • The issue of falling antibody levels in convalescing patients
  • COVID health impacts on survivors

Get the PDF

 

 

6. Detailed virus reports by state

  • One-page reports on each state with charts on infections, hospitalizations, mortality, testing levels, positive test rates, hospital bed/ICU utilization rates and doctor visit indicators

Get the PDF

 

This compilation incorporates research and feedback from the Johns Hopkins University Center for Health Security, Harvard Medical School, the University of Toronto Dalla Lana School of Public Health, Washington University Biomedical Sciences Department, the Imperial College of London Department of Infectious Disease Epidemiology and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

 

 

 

 

 

Check the background of Our Firm and Investment Professionals on FINRA's BrokerCheck

To learn more about J. P. Morgan’s investment business, including our accounts, products and services, as well as our relationship with you, please review our  J.P. Morgan Securities LLC Form CRS and  Guide to Investment Services and Brokerage Products.

This website is for informational purposes only, and not an offer, recommendation or solicitation of any product, strategy service or transaction. Any views, strategies or products discussed on this site may not be appropriate or suitable for all individuals and are subject to risks. Prior to making any investment or financial decisions, an investor should seek individualized advice from a personal financial, legal, tax and other professional advisors that take into account all of the particular facts and circumstances of an investor's own situation. 

This website provides information about the brokerage and investment advisory services provided by J.P. Morgan Securities LLC (JPMS). When JPMS acts as a broker-dealer, a client's relationship with us and our duties to the client will be different in some important ways than a client's relationship with us and our duties to the client when we are acting as an investment advisor. A client should carefully read the agreements and disclosures received (including our Form ADV disclosure brochure, if and when applicable) in connection with our provision of services for important information about the capacity in which we will be acting.

INVESTMENT AND INSURANCE PRODUCTS ARE: • NOT FDIC INSURED • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY • NOT A DEPOSIT OR OTHER OBLIGATION OF, OR GUARANTEED BY, JPMORGAN CHASE BANK, N.A. OR ANY OF ITS AFFILIATES • SUBJECT TO INVESTMENT RISKS, INCLUDING POSSIBLE LOSS OF THE PRINCIPAL AMOUNT INVESTED

Equal Housing Opportunity logo

J.P. Morgan Chase Bank N.A., Member FDIC. Not a commitment to lend. All extensions of credit are subject to credit approval.

Investments in alternative investment strategies is speculative, often involves a greater degree of risk than traditional investments including limited liquidity and limited transparency, among other factors and should only be considered by sophisticated investors with the financial capability to accept the loss of all or part of the assets devoted to such strategies.

Borrowing with securities as collateral involves certain risks, including the possibility that you may need to deposit additional securities and/or cash in the account to meet a maintenance call, and that securities in the account may be sold to meet the maintenance call.  Proper management of your account and a thorough understanding of the conditions that may affect your investments will assist you in effectively using the margin lending program.​

J.P. Morgan Wealth Management is a business of JPMorgan Chase & Co., which offers investment products and services through J.P. Morgan Securities LLC (JPMS), a registered broker-dealer and investment advisor, member FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. Certain custody and other services are provided by JPMorgan Chase Bank, N.A. (JPMCB). JPMS, CIA and JPMCB are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

Please read additional Important Information in conjunction with these pages.